Corbus Pharmaceuticals Stock Surges on Promising Phase 1b Obesity Drug Data

Shares of Corbus Pharmaceuticals (NASDAQ: CRBP) surged more than 14% in pre-market trading on Tuesday after the company released positive topline data from its Phase 1b clinical trial for CRB-913, a once-daily oral treatment for obesity.

Key Trial Findings

Corbus announced that the CANYON-1 study, a 16-week, double-blind, placebo-controlled trial involving 254 obese, non-diabetic adults, met its primary endpoints. The results showed statistically significant and clinically meaningful weight loss across all three doses tested.

Key takeaways from the data include:

• The highest dose evaluated, 60 mg, resulted in a mean weight loss of 5% from baseline at 12 weeks, with the company noting that a plateau had not been reached.
• The 40 mg and 20 mg doses achieved placebo-adjusted weight losses of 3.3% and 2.8%, respectively.

Market Impact and Competitive Outlook

Ad

The market's strong positive reaction was driven not only by the efficacy data but also by the drug's safety profile. Corbus reported that CRB-913 was associated with fewer gastrointestinal adverse events compared to currently marketed oral GLP-1 drugs, a significant potential differentiator in the highly competitive obesity treatment market.

The stock's advance was entirely company-specific, standing in sharp contrast to a weaker broader market in pre-open trading. The positive data provides a crucial validation for CRB-913's mechanism and positions Corbus as a credible new entrant in the lucrative oral obesity drug space.

Next Steps

Corbus outlined a clear development path for CRB-913, which helped bolster investor confidence. The company plans to present the full dataset from the CANYON-1 trial at the ObesityWeek 2026 conference in November.

Following the data presentation, Corbus intends to engage with the U.S. Food and Drug Administration (FDA) to finalize its clinical development plan. The company aims to initiate a Phase 2 monotherapy study in the first half of 2027.